FCGR多态性对单克隆抗体抗肿瘤治疗的疗效预测价值  

The predictive value of FCGR polymorphisms for anticancer therapeutic response to monoclonal antibodies

作　　者：徐玲[1] 刘云鹏[1] 

机构地区：[1]中国医科大学附属第一医院肿瘤内科,辽宁沈阳110001

出　　处：《现代肿瘤医学》2015年第19期2875-2878,共4页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:81201802);辽宁省自然科学基金项目(编号:2014021069)

摘　　要：抗体依赖细胞介导的细胞毒作用(ADCC)是单克隆抗体如西妥昔单抗,利妥昔单抗,曲妥珠单抗发挥抗肿瘤作用的主要机制。FCG受体(FCGR)主要在人白细胞上,在ADCC中发挥重要作用。单克隆抗体的疗效与FCGR多态性密切相关,其中FCGR2A(H131R)和FCGR3A(V158F)是主要的基因型。这篇文章对FCGR多态性对单克隆抗体在肿瘤患者中的疗效预测价值做一综述。Antibody - dependent cellular cytotoxicity（ADCC）is a major mechanism of action of monoclonal anti-bodies such as cetuximab,rituximab and trastuzumab. Fc gamma receptors（FCGR）are mainly on human white blood cells,and play an important role on ADCC. The response to monoclonal antibodies is correlated with FCGR polymor-phisms,among which FCGR2A（H131R）and FCGR3A（V158F）are main genotypes. This review will discuss exam-ines the current evidence for FCGR polymorphisms to predict the response to monoclonal antibodies in patients with cancer.

关 键 词：抗体依赖细胞介导的细胞毒作用 西妥昔单抗 利妥昔单抗 曲妥珠单抗 

分 类 号：R730.5[医药卫生—肿瘤]